Zimmer Biomet director granted phantom stock units

HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.

Zimmer Biomet Holdings, Inc. director Robert Hagemann reported receiving a grant of 308.711 Phantom Stock Units on March 31, 2026. These units are tied 1-for-1 to the company’s common stock value and increase his deferred balance to 31,982.841 units.

The units were accrued under Zimmer Biomet’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash in five annual installments after his board service ends. His balance also includes 87.178 phantom units added earlier under the plan’s dividend reinvestment provision.

Insider Trade Summary

Grant/Award: 308.711 shares

Grant/Award 1 txn

Insider HAGEMANN ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units	308.711	$0.00	$0.00

Holdings After Transaction: Phantom Stock Units — 31,982.841 contracts (Direct)

Footnotes (4)

1. F1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
2. F2. The Conversion or Exercise Price of Derivative Security is 1-for-1.
3. F3. Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
4. F4. Includes 87.178 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Key Figures

Phantom units granted: 308.711 units Total phantom units after grant: 31,982.841 units Dividend reinvestment units: 87.178 units +2 more

5 metrics

Phantom units granted 308.711 units Grant on March 31, 2026 to director Robert Hagemann

Total phantom units after grant 31,982.841 units Deferred compensation balance following the March 31, 2026 award

Dividend reinvestment units 87.178 units Accrued on January 30, 2026 under dividend reinvestment provision

Conversion ratio 1-for-1 Phantom Stock Units track Zimmer Biomet common stock value

Installment count 5 annual installments Cash settlement schedule after end of director’s service year

Key Terms

Phantom Stock Units, Deferred Compensation Plan for Non-Employee Directors, dividend reinvestment provision, settled in cash

4 terms

Phantom Stock Units financial

"The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Deferred Compensation Plan for Non-Employee Directors financial

"The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

dividend reinvestment provision financial

"Includes 87.178 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors."

A dividend reinvestment provision is a company policy that lets shareholders automatically use their cash dividends to buy more shares instead of receiving money. Think of it like a subscription that turns each payday into buying an extra slice of the same pie; it helps investors compound their holdings over time, often with lower transaction costs and sometimes at a small discount, which can boost long‑term returns and subtly change ownership percentages.

settled in cash financial

"Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs."

FAQ

What insider transaction did ZIMMER BIOMET (ZBH) director Robert Hagemann report?

Robert Hagemann reported receiving 308.711 Phantom Stock Units on March 31, 2026. These derivative units track Zimmer Biomet common stock value and were granted under the Deferred Compensation Plan for Non-Employee Directors as a compensation-related award, not an open-market purchase or sale.

What are Phantom Stock Units in the ZIMMER BIOMET (ZBH) Form 4 filing?

Phantom Stock Units are derivative awards whose value mirrors Zimmer Biomet common stock on a 1-for-1 basis. They are accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are ultimately settled in cash rather than delivering actual common shares to the director.

How many Phantom Stock Units does the ZBH director hold after this transaction?

After the March 31, 2026 grant of 308.711 Phantom Stock Units, Robert Hagemann’s reported balance under the plan totals 31,982.841 units. This figure reflects his entire phantom unit position directly held through the deferred compensation arrangement at that time.

How and when will the ZIMMER BIOMET (ZBH) Phantom Stock Units be settled?

The Phantom Stock Units will be settled in cash, not shares, in five annual installments. Payments begin within sixty days after the end of the calendar year in which Robert Hagemann’s service as a Zimmer Biomet director ceases, according to the plan’s terms.

What is the significance of the 87.178 Phantom Stock Units mentioned in the ZBH filing?

The 87.178 Phantom Stock Units were accrued on January 30, 2026 through the plan’s dividend reinvestment provision. This means phantom equivalents of dividends were reinvested into additional units, increasing Robert Hagemann’s deferred compensation balance linked to Zimmer Biomet’s common stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAGEMANN ROBERT

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW INDIANA 46580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units(1)	$89.08(2)	03/31/2026		A		308.711		(3)	(3)	Common Stock	308.711	$0	31,982.841(4)	D

Explanation of Responses:

1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

2. The Conversion or Exercise Price of Derivative Security is 1-for-1.

3. Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

4. Includes 87.178 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Robert Hagemann (power of attorney previously filed)	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)